SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Clinical trials for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS explained in plain language.
Never miss a new study
Get alerted when new SLE - SYSTEMIC LUPUS ERYTHEMATOSUS trials appear
Sign up with your email to follow new studies for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at childhood autoimmune diseases
Disease control Not yet recruitingThis early-phase trial tests a single infusion of universal CAR-T cells (RD06-05) in 30 children and adolescents with severe autoimmune diseases, including lupus, scleroderma, and kidney inflammation. The cells are designed to target and calm overactive immune cells. The main goa…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Off-the-Shelf CAR-Ts take on lupus and more
Disease control Not yet recruitingThis early-phase trial tests a single dose of universal (off-the-shelf) CAR-T cells in 30 adults with active autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's. The treatment targets CD19 and BCMA on immune cells to reset the faulty immune system. The…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Engineered immune cells take on lupus kidney disease
Disease control Not yet recruitingThis phase 2 trial is testing a new treatment called FT819 for people with lupus nephritis, a serious kidney complication of lupus. FT819 is made from donor immune cells that are engineered to target and destroy faulty B cells. The study will enroll 53 participants and aims to se…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: PHASE2 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New lupus drug candidate enters human safety testing
Disease control Not yet recruitingThis early-stage study tests a new drug called IASO-782 in 20 adults with systemic lupus erythematosus (SLE). The main goal is to see if the drug is safe and tolerable. Participants will receive either the drug or a placebo, and researchers will monitor for side effects.
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: PHASE1 • Sponsor: Shanghai IASO Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Engineered immune cells take on lupus in early trial
Disease control Not yet recruitingThis early-phase study tests a new treatment called CD19/BCMA CAR-T cell therapy for adults with refractory systemic lupus erythematosus (SLE) that hasn't improved with standard treatments. About 24 participants will receive a single infusion of their own engineered immune cells …
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: EARLY_PHASE1 • Sponsor: Chengdu Ucello Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Could a stomach infection worsen lupus? new study investigates
Knowledge-focused Not yet recruitingThis observational study will check if having an H. pylori stomach infection is linked to more active lupus in 115 adults. Researchers will use a stool test to detect the bacteria and a standard lupus score to measure disease activity. No treatments are given; the goal is simply …
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:10 UTC